AstraZeneca efzimfotase alfa posts 17.05-meter 6MWT gain vs placebo in HICKORY Phase III HPP trial
AZN•AstraZeneca said efzimfotase alfa showed a 17.05-meter gain on the 6-minute walk test versus placebo in its Phase III HICKORY trial, but the study missed its main goal. Secondary measures suggested benefits in fatigue and pain, and the drug has U.S. FDA Priority Review.
1. Trial results
AstraZeneca disclosed Phase III HICKORY results for efzimfotase alfa in hypophosphatasia, presented at ASBMR 2026. The study missed its main goal versus placebo, though treated patients showed signs of improved walking ability, with a 17.05-meter gain on the 6-minute walk test.
2. Other measures
Several secondary measures suggested benefits in fatigue and pain, with improvements continuing during the extension period. The drug has U.S. FDA Priority Review; the rare-disease market is currently served by Strensiq.
